Is NCI-C56235 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use NCI-C56235? Is NCI-C56235 safe for nursing mother and child? Does NCI-C56235 extracts into breast milk? Does NCI-C56235 has any long term or short term side effects on infants? Can NCI-C56235 influence milk supply or can NCI-C56235 decrease milk supply in lactating mothers?
NCI-C56235 lactation summary
- DrLact safety Score for NCI-C56235 is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of NCI-C56235 may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that NCI-C56235 may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of NCI-C56235 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using NCI-C56235 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About NCI-C56235 usage in lactation
Skeletal muscle relaxant with sedative effects on the central nervous system. It is metabolized to meprobamate.Indicated on low back pain. It is excreted into breast milk in a clinically non-significant amount (Nordeng 2001, Bailey 2002, Briggs 2008) without problems being observed on infants whose mothers were receiving this medication, (Nordeng 2001), except for a mild sedation with higher maternal drug doses (Briggs 2008) .Plasma levels in the infant were undetectable (Briggs 2008). NCI-C56235 use increases the risk of abuse and addictive behavior, intoxication and possible psychomotor impairment (Bailey 2002, EMA 2007) being such a reason to be withdrawn from the market in some countries. The European Medicines Agency (EMA) has recommended to withhold authorizations for marketing of medicines that contains NCI-C56235 (EMA 2007, Reeves 2012, Bramases 2012). If administered during breastfeeding, it is advisable to use a minimum effective dose and monitor a possible sedation on the infant and an inadequate milk production (Sachs 2013).
Answer by DrLact: About NCI-C56235 usage in lactation
If NCI-C56235 is required by the mother, it is not necessarily a reason to discontinue breastfeeding. Slight sedation has occurred in a breastfed newborn infant who was exposed during pregnancy and lactation; sedation might be more pronounced in newborns who are exposed for the first time during nursing. Other agents may be preferred, especially while nursing a newborn or preterm infant, or when other drugs that can cause sedation are used simultaneously.
NCI-C56235 Side Effects in Breastfeeding
A mother taking NCI-C56235 700 mg plus propoxyphene 70 mg and acetaminophen 900 mg 3 times daily and partially breastfeeding her infant noticed no unusual behavior or adverse reactions in her infant. The infant grew normally and at 6 months of age, examination by a pediatrician found normal psychomotor development.[1] A mother took NCI-C56235 700 mg orally four times daily at 4- to 6-hour intervals during pregnancy and while exclusively nursing her newborn infant. Slight sedation of the infant was noted during the first month of life.[3]
Alternate Drugs
Meprobamate(Low Risk)
Cyclobenzaprine(Low Risk)
Dantrolene(Unsafe)
Carisoprodol(Low Risk)
Baclofen(Safe)